BioXcel Therapeutics reports strong correlation between clinician & caregiver agitation scales; sNDA planned Q1 2026

BioXcel Therapeutics, Inc.

Correlation study (N=33) shows ρ=0.89 (patient) and ρ=0.88 (informant) between PEC and mCGI-S scales, p<0.0001.
No serious adverse events; safety profile consistent with IGALMI label.
Results to be included in sNDA submission for BXCL501 planned for Q1 2026.
mCGI-S scale developed with FDA for at-home efficacy assessment of acute agitation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.